Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine

Vitaly A. Kushnir, David Seifer, David H. Barad, Aritro Sen, Norbert Gleicher

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-Müllerian hormone (AMH) which is also commonly known as Müllerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine. Therapeutic uses of AMH in gonadal tissue may provide a unique opportunity to address a broad range of reproductive themes, like contraception, ovulation induction, onset of menopause, and fertility preservation, as well as specific disease conditions, such as polycystic ovarian syndrome (PCOS) and cancers of the reproductive tract. This review explores the most promising therapeutic applications for a novel class of drugs known as AMH analogues with agonist and antagonist functions.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of Assisted Reproduction and Genetics
DOIs
StateAccepted/In press - Jun 22 2017
Externally publishedYes

Fingerprint

Reproductive Medicine
Hormones
Transforming Growth Factor beta
Fertility Preservation
Physiological Phenomena
Gonadal Hormones
Ovulation Induction
Polycystic Ovary Syndrome
Therapeutic Uses
Therapeutics
Menopause
Contraception
Ovarian Neoplasms
Biomarkers
Pharmaceutical Preparations

Keywords

  • AMH agonist
  • AMH analogues
  • AMH antagonist
  • Anti-Müllerian hormone
  • Contraception
  • Endometrial cancer
  • Fertility preservation
  • Fertility treatment
  • Menopause
  • Müllerian inhibiting substance
  • Ovarian cancer
  • Ovulation induction
  • Polycystic ovarian syndrome

ASJC Scopus subject areas

  • Reproductive Medicine
  • Genetics
  • Obstetrics and Gynecology
  • Developmental Biology
  • Genetics(clinical)

Cite this

Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. / Kushnir, Vitaly A.; Seifer, David; Barad, David H.; Sen, Aritro; Gleicher, Norbert.

In: Journal of Assisted Reproduction and Genetics, 22.06.2017, p. 1-9.

Research output: Contribution to journalArticle

Kushnir, Vitaly A. ; Seifer, David ; Barad, David H. ; Sen, Aritro ; Gleicher, Norbert. / Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. In: Journal of Assisted Reproduction and Genetics. 2017 ; pp. 1-9.
@article{8d9659a5bec54a24afd5e007ed352a98,
title = "Potential therapeutic applications of human anti-M{\"u}llerian hormone (AMH) analogues in reproductive medicine",
abstract = "Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-M{\"u}llerian hormone (AMH) which is also commonly known as M{\"u}llerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine. Therapeutic uses of AMH in gonadal tissue may provide a unique opportunity to address a broad range of reproductive themes, like contraception, ovulation induction, onset of menopause, and fertility preservation, as well as specific disease conditions, such as polycystic ovarian syndrome (PCOS) and cancers of the reproductive tract. This review explores the most promising therapeutic applications for a novel class of drugs known as AMH analogues with agonist and antagonist functions.",
keywords = "AMH agonist, AMH analogues, AMH antagonist, Anti-M{\"u}llerian hormone, Contraception, Endometrial cancer, Fertility preservation, Fertility treatment, Menopause, M{\"u}llerian inhibiting substance, Ovarian cancer, Ovulation induction, Polycystic ovarian syndrome",
author = "Kushnir, {Vitaly A.} and David Seifer and Barad, {David H.} and Aritro Sen and Norbert Gleicher",
year = "2017",
month = "6",
day = "22",
doi = "10.1007/s10815-017-0977-4",
language = "English (US)",
pages = "1--9",
journal = "Journal of Assisted Reproduction and Genetics",
issn = "1058-0468",
publisher = "Springer New York",

}

TY - JOUR

T1 - Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine

AU - Kushnir, Vitaly A.

AU - Seifer, David

AU - Barad, David H.

AU - Sen, Aritro

AU - Gleicher, Norbert

PY - 2017/6/22

Y1 - 2017/6/22

N2 - Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-Müllerian hormone (AMH) which is also commonly known as Müllerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine. Therapeutic uses of AMH in gonadal tissue may provide a unique opportunity to address a broad range of reproductive themes, like contraception, ovulation induction, onset of menopause, and fertility preservation, as well as specific disease conditions, such as polycystic ovarian syndrome (PCOS) and cancers of the reproductive tract. This review explores the most promising therapeutic applications for a novel class of drugs known as AMH analogues with agonist and antagonist functions.

AB - Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-Müllerian hormone (AMH) which is also commonly known as Müllerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine. Therapeutic uses of AMH in gonadal tissue may provide a unique opportunity to address a broad range of reproductive themes, like contraception, ovulation induction, onset of menopause, and fertility preservation, as well as specific disease conditions, such as polycystic ovarian syndrome (PCOS) and cancers of the reproductive tract. This review explores the most promising therapeutic applications for a novel class of drugs known as AMH analogues with agonist and antagonist functions.

KW - AMH agonist

KW - AMH analogues

KW - AMH antagonist

KW - Anti-Müllerian hormone

KW - Contraception

KW - Endometrial cancer

KW - Fertility preservation

KW - Fertility treatment

KW - Menopause

KW - Müllerian inhibiting substance

KW - Ovarian cancer

KW - Ovulation induction

KW - Polycystic ovarian syndrome

UR - http://www.scopus.com/inward/record.url?scp=85021139810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021139810&partnerID=8YFLogxK

U2 - 10.1007/s10815-017-0977-4

DO - 10.1007/s10815-017-0977-4

M3 - Article

C2 - 28643088

AN - SCOPUS:85021139810

SP - 1

EP - 9

JO - Journal of Assisted Reproduction and Genetics

JF - Journal of Assisted Reproduction and Genetics

SN - 1058-0468

ER -